The South African Health Products Regulatory Authority recently approved the use of the monthly dapivirine vaginal ring for women 18 years and older to reduce the risk of HIV infection. Thabo Molelekwa looks at the evidence for the ring’s efficacy and asks what plans there are for making it available to women in South Africa.
While various medicines are produced in South Africa, the active pharmaceutical ingredients going into these medicines are mostly still imported. Catherine Tomlinson reports on a local company that is trying to change that – starting with active pharmaceutical ingredients for tuberculosis and COVID-19 medicines.
At an estimated R27 billion per year, the cost of corruption equates to about 10% of the country’s total budget for health in 2022. With procurement understood to be a government’s single greatest corruption risk – health contracts are especially vulnerable. This is why reform related to safeguarding public procurement and resources is now beyond urgent, argues Zukiswa Kota.
The period covered by South Africa’s National Strategic Plan (NSP) for HIV, TB, and STIs 2017 – 2022 will soon come to an end. Against the backdrop of another World TB Day, Tiyese Jeranji asked several local tuberculosis experts what they think the TB priorities should be as South Africa develops an NSP for the next five years.
It is estimated that over 100 000 of the over 300 000 people who fall ill with TB in South Africa every year are not diagnosed. As a result, improving TB screening and testing has become a high priority in South Africa’s TB response. Coinciding with World TB Day 2022, Spotlight editor Marcus Low examines new information shared by the National Department of Health and assesses the state of the country’s TB case-finding efforts.
Long-acting injections have been successfully used as contraception and more recently HIV prevention. Now researchers are exploring whether similar long-acting injections could be used for the prevention and treatment of tuberculosis. Tiyese Jeranji reports.
Investing in tuberculosis means that everyone has a stake in eliminating TB as a public health threat in our country: every person, every family, every community, every organisation (public and private) as well as government, writes Dr Yogan Pillay and Gaurang Tanna.
Dr Jennifer Furin has fought drug-resistant tuberculosis (TB) since 1995, when she worked as a student in a poverty-stricken suburb in Lima, Peru. Since then she has roamed the world, treating TB and HIV patients in under-resourced countries, including Haiti, Russia, Tajikistan, Bangladesh, eSwatini, Lesotho, and South Africa. Biénne Huisman chatted to Furin about her life working in TB and what it means to see things from the perspective of people living with TB.
For healthcare, a post-pandemic human rights-focused budget would have allocated funding specifically for backlogs in access to health services from the past two years, as well as tackling the present inequities in access to healthcare that characterise the public health system. Tshidi Lencoasa, Khanyisa Mapipa, and Julia Chaskalson argue that this year’s budget does not do enough to enable government to realise people’s fundamental human right to access healthcare.
There is nothing humans can do about the fact that everyone dies eventually, but there may be room to do better when it comes to how some doctors, nurses, and care workers break the news of dying and death; and also how they give practical support to a grieving family. Ufrieda Ho looks at what measures are in place to guide healthcare workers, patients, and their families through this process in health facilities.
In February, Stix Morewa Hospital in Selby, Johannesburg sent out a letter to the families of the over 400 mental healthcare users in their care. In this letter, families were reportedly informed that the Gauteng Department of Health will terminate its contract with the hospital by the end of March, which would have meant that the mental health users would have had to be transferred elsewhere. Thabo Molelekwa looks at the developments since then.
Broadly neutralising antibodies (bnAbs) are one of the most active and exciting areas in HIV research. Last year Spotlight reported on a “proof of concept” study showing that a specific bnAb can successfully prevent infection with certain strains of HIV. Now, we also have intriguing findings suggesting that bnAbs may have a role to play in the treatment of HIV in children. Elri Voigt reports.
